Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 0,38 M
EBIT 2015 -38,9 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 0,59 M
EBIT 2016 -38,8 M
Net income 2016 -35,9 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 224x
Capi. / Sales 2016 143x
Capitalization 85,0 M
More Financials
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Latest news on CEL-SCI CORPORATION
04/16 CEL SCI : Adds Aintree University Hospital to Phase III Head and Neck Cancer Tri..
04/13 CEL SCI : NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III H..
04/13 CEL SCI : UK’s Aintree University Hospital Joins CEL-SCI’s Phase III..
04/02 CEL SCI : Other Events (form 8-K)
04/01 CEL SCI : NEW STORY CEL-SCI Reports 3rd Consecutive Month of Record Patient Enro..
04/01 CEL SCI : Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for..
03/18 CEL SCI : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form ..
03/12 CEL-SCI CORPORATION : Cel-Sci's Cancer Immunotherapy In Phase III Is Value Oppor..
More news
Sector news : Bio Therapeutic Drugs
04/17 INCYTE : Emerging Development Pipeline Described in Eleven Abstracts at 2015 AAC..
04/16 QIAGEN NV : N.V. : to Report First Quarter 2015 Results
04/16 Receptos Reports Positive Results for the Maintenance Period of the Phase 2 T..
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF